Thompson Investment Management Inc. Decreases Position in Teleflex Incorporated (NYSE:TFX)

Thompson Investment Management Inc. decreased its stake in Teleflex Incorporated (NYSE:TFXFree Report) by 6.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,340 shares of the medical technology company’s stock after selling 150 shares during the period. Thompson Investment Management Inc.’s holdings in Teleflex were worth $583,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. lifted its holdings in Teleflex by 2.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 8,633,473 shares of the medical technology company’s stock worth $2,155,174,000 after buying an additional 181,393 shares during the last quarter. Vanguard Group Inc. increased its position in Teleflex by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 5,147,062 shares of the medical technology company’s stock valued at $1,826,333,000 after acquiring an additional 83,858 shares during the period. BlackRock Inc. increased its position in shares of Teleflex by 0.3% during the 1st quarter. BlackRock Inc. now owns 3,982,749 shares of the medical technology company’s stock valued at $1,008,870,000 after purchasing an additional 13,204 shares during the period. Morgan Stanley boosted its stake in shares of Teleflex by 535.8% during the 4th quarter. Morgan Stanley now owns 2,691,192 shares of the medical technology company’s stock worth $671,803,000 after acquiring an additional 2,267,889 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of Teleflex by 1.4% during the 2nd quarter. State Street Corp now owns 2,361,882 shares of the medical technology company’s stock worth $571,646,000 after acquiring an additional 32,925 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Trading Down 1.5 %

Teleflex stock opened at $220.94 on Monday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.29 and a current ratio of 2.32. The business’s 50-day simple moving average is $237.77 and its 200-day simple moving average is $223.92. The firm has a market capitalization of $10.40 billion, a PE ratio of 29.34, a PEG ratio of 2.12 and a beta of 1.11. Teleflex Incorporated has a 52 week low of $177.63 and a 52 week high of $276.43.

Teleflex (NYSE:TFXGet Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The medical technology company reported $3.38 EPS for the quarter, topping analysts’ consensus estimates of $3.26 by $0.12. Teleflex had a return on equity of 14.98% and a net margin of 11.98%. The business had revenue of $773.90 million for the quarter, compared to analyst estimates of $769.01 million. During the same period in the previous year, the company posted $3.52 earnings per share. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. Equities research analysts forecast that Teleflex Incorporated will post 13.73 earnings per share for the current year.

Teleflex Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, March 15th. Investors of record on Friday, March 1st were paid a dividend of $0.34 per share. The ex-dividend date was Thursday, February 29th. This represents a $1.36 annualized dividend and a yield of 0.62%. Teleflex’s dividend payout ratio is 18.06%.

Insider Activity at Teleflex

In related news, CEO Liam Kelly sold 26,256 shares of the business’s stock in a transaction dated Wednesday, December 27th. The stock was sold at an average price of $250.23, for a total transaction of $6,570,038.88. Following the transaction, the chief executive officer now directly owns 18,470 shares in the company, valued at $4,621,748.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Teleflex news, CEO Liam Kelly sold 26,256 shares of the company’s stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $250.23, for a total transaction of $6,570,038.88. Following the completion of the sale, the chief executive officer now owns 18,470 shares in the company, valued at approximately $4,621,748.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Cameron P. Hicks sold 7,401 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $225.00, for a total transaction of $1,665,225.00. Following the sale, the vice president now owns 10,050 shares of the company’s stock, valued at approximately $2,261,250. The disclosure for this sale can be found here. Corporate insiders own 1.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Royal Bank of Canada decreased their target price on Teleflex from $272.00 to $265.00 and set an “outperform” rating for the company in a research report on Friday, February 23rd. JMP Securities reissued a “market outperform” rating and set a $285.00 price objective on shares of Teleflex in a research report on Friday, February 23rd. Morgan Stanley raised Teleflex from an “equal weight” rating to an “overweight” rating and set a $261.00 price objective for the company in a research report on Monday, December 4th. Truist Financial reduced their price objective on Teleflex from $270.00 to $265.00 and set a “hold” rating for the company in a research report on Friday, February 23rd. Finally, Raymond James lifted their price objective on Teleflex from $227.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday, December 20th. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Teleflex currently has an average rating of “Moderate Buy” and a consensus target price of $265.56.

Check Out Our Latest Stock Report on TFX

Teleflex Company Profile

(Free Report)

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

See Also

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFXFree Report).

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.